Therapeutic targeting of HER2–CB <sub>2</sub> R heteromers in HER2-positive breast cancerSandra Blasco-Benito(Universidad Complutense de Madrid), Cristina Sánchez(Research Institute Hospital 12 de Octubre)Proceedings of the National Academy of SciencesFebruary 7, 201910.1073/pnas.1815034116Cited by 62SaveCiteExport RISWatch citationsRelated PapersCannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition|Molecular Cancer|2010|193Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer|Oncotarget|2016|51